argenx SE (ARGX) PT Raised to $675 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
argenx SE (ARGX) PT Raised to $707 at Jefferies
November 22, 2024 11:07 AM ESTJefferies analyst Akash Tewari raised the price target on argenx SE (NASDAQ: ARGX) to $707.00 (from $689.00) while maintaining a Buy rating.
The analyst comments "Myositis: 1) It was an easy decision for ARGX as they're seeing a clear signal across all 3 myositis subsets including on secondary endpoints like time to response & deep responses - it's also fair to assume that historical IVIG data would be considered as reference point when setting "go" threshold, 2) ARGX just got the data & the team will be looking to see if they can benefit from making any changes... More
